Clinical Trials: Page 16
-
Getty Images
Sponsored by FortreaBridging science and humanity: Systems thinking in clinical trial design
Benefits of adopting the systems thinking approach in clinical trial design.
By Clare Campbell-Cooper, Global Head of Digital Health and Innovation at FORTREA • June 24, 2024 -
Getty Images
Obesity drug from Zealand shows potential in early trial
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
By Jonathan Gardner • June 20, 2024 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Getty Images
FDA lifts hold on PTC Huntington’s disease trial
The agency has lifted a partial trial suspension based on one-year data showing PTC’s pill suppressed a key protein associated with the disorder.
By Jonathan Gardner • June 20, 2024 -
Permission granted by Gilead Sciences
Twice-yearly shots of Gilead HIV drug effective in large prevention study
Researchers recommended Gilead end testing early as lenacapavir proved 100% effective in protecting cisgender women in the Phase 3 trial.
By Ned Pagliarulo • June 20, 2024 -
Elizabeth Regan/BioPharma Dive
Intra-Cellular depression drug succeeds in second late-stage study
The results position the company to unlock what’s believed to be a multibillion-dollar sales opportunity for Caplyta, which is already used to treat schizophrenia and bipolar disorder.
By Kristin Jensen • June 18, 2024 -
Getty Images
Takeda drug for rare types of epilepsy misses goal in late-stage trial
Called soticlestat, the drug had seemed promising in earlier studies for people with Dravet and Lennox-Gastaut syndrome, enough to persuade Takeda to take on full rights to the drug.
By Jonathan Gardner • June 17, 2024 -
Getty Images
Immune resetNew data showcase promise, growing pains of CAR-T in autoimmune disease
One expert described trial results presented at EULAR in June as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
By Ben Fidler • June 17, 2024 -
Permission granted by PetersenWest/MenariniSilicon Biosystems
Sponsored by Menarini Silicon BiosystemsThe critical role of comprehensive RNA sequencing in liquid biopsy for biomarker discovery and clinical trials
Elevate precision medicine: dose optimization and immune monitoring through advanced liquid biopsies.
By Harshil Patel, MBA, CGMBS, ASCP - Sr. Marketing Manager • June 17, 2024 -
Joe Raedle/Getty Images via Getty Images
Moderna says next-gen COVID shot effective in study
Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.
By Kristin Jensen • June 13, 2024 -
Getty Images
Pfizer gene therapy for Duchenne fails to meet goals of key trial
The negative results from the Phase 3 study, called Ciffreo, come a little more than a month after Pfizer said a patient died in another trial of the gene therapy.
By Ned Pagliarulo , Ben Fidler • June 12, 2024 -
Permission granted by Ultragenyx
Ultragenyx, Mereo drug reduces fractures in bone disorder study
New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.
By Kristin Jensen • June 12, 2024 -
Maddie Meyer via Getty Images
Moderna says combination flu, COVID shot succeeds in study
Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025.
By Delilah Alvarado • June 10, 2024 -
Getty Images
After ‘sobering’ FDA panel, psychedelics supporters wonder what’s next
A vote against MDMA-assisted therapy set back a high-profile treatment. Proponents argue the panel offered few solutions to longstanding problems, making the path forward unclear.
By Jacob Bell • June 7, 2024 -
Alyssa Eckel-Martin/BioPharma Dive
Sponsored by BioLineRx[Podcast] The Power of Persistence: From Biotech Incubator to Product Launch
How can small and mid-sized biotech companies better manage pharmacovigilance during clinical trials? Listen to the podcast to learn how strategic alliances are helping.
By BioPharma Dive's studioID • Updated June 18, 2024 -
Sarah Silbiger via Getty Images
FDA panel votes against MDMA therapy for PTSD, citing muddy data and safety concerns
“I just feel very convinced that I had to vote no,” said one member of the committee, which was unconvinced by Lykos Therapeutics’ data on MDMA-assisted treatment for post-traumatic stress disorder.
By Jacob Bell • Updated June 4, 2024 -
Getty Images
Viking says biopsy data confirm MASH drug’s benefit
The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.
By Jonathan Gardner • June 4, 2024 -
Getty Images
BridgeBio data show sustained benefit for achondroplasia drug
Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.
By Ned Pagliarulo • June 4, 2024 -
ASCO / Nick Agro
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
AstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an alternative cell therapy strategy that will delay its study plans.
By BioPharma Dive staff • June 3, 2024 -
Spencer Platt via Getty Images
Structure pill leads to competitive weight loss in obesity study
Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.
By Delilah Alvarado • June 3, 2024 -
Menarini Silicon Biosystems
Sponsored by Menarini Silicon BiosystemsA true liquid biopsy hub – Menarini Silicon Biosystem
Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights into disease progression and treatment response.
June 3, 2024 -
ASCO / Nick Agro
GSK builds case for return of multiple myeloma drug Blenrep
Study results showed the antibody-drug conjugate helped stave off disease progression better than a standard treatment. But eye-related side effects remained common.
By Jonathan Gardner • June 2, 2024 -
Permission granted by Daiichi Sankyo
With new Enhertu data, an ADC could overtake chemo in breast cancer
The results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca and Daiichi Sankyo see replacing chemo in many tumors.
By Ben Fidler • June 2, 2024 -
Jonathan Gardner/BioPharma Dive
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
The findings, from a trial testing Imfinzi in limited-stage small cell lung cancer, could help AstraZeneca expand the drug's use.
By Jonathan Gardner • Updated June 2, 2024 -
Justin Sullivan via Getty Images
Gilead’s Trodelvy misses goal in bladder cancer study
Treatment didn’t significantly improve overall survival in the trial, a finding that one analyst described as a “meaningful setback” to Gilead’s oncology pipeline.
By Ned Pagliarulo • May 31, 2024 -
Getty Images
Novartis study points to larger role for targeted leukemia drug
Results from a trial called ASC4FIRST show Scemblix outperformed Gleevec and other drugs in treating newly diagnosed chronic myeloid leukemia.
By Ned Pagliarulo • Updated June 3, 2024
Previous
